Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5a

9 Nov 2015 11:56

RNS Number : 0362F
GoldmanSachs International
09 November 2015
 

Ap24

 

FORM 38.5(a)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

Name of exempt principal trader

(GS) GOLDMAN SACHS INTERNATIONAL

Company dealt in

PFIZER INC

Class of relevant security to which the dealings being disclosed relate (Note 1)

USD Ordinary

Date of dealing

06 November 2015

 

2. DEALINGS (Note 2)

 

(a) Purchases and sales

 

Total number of relevant securities acquired

Highest price paid (Note 3)

Lowest price paid

(Note 3)

7,701

33.9300 USD

33.4600 USD

 

Total number of securities disposed

Highest price received (Note 3)

Lowest price received

(Note 3)

7,701

33.8900 USD

33.4100 USD

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 4)

Number of relevant securities

(Note 5)

Price per unit

(Note 3)

 

Ap25

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

Call Option / (1.00 : 100.00)

Purchasing

20 (2,000)

34.0000 USD

AMERICAN

20/11/2015

0.4600 USD

Call Option / (1.00 : 100.00)

Purchasing

41 (4,100)

34.0000 USD

AMERICAN

20/11/2015

0.3800 USD

Call Option / (1.00 : 100.00)

Selling

1 (100)

35.0000 USD

AMERICAN

20/11/2015

0.1900 USD

Call Option / (1.00 : 100.00)

Selling

11 (1,100)

35.0000 USD

AMERICAN

20/11/2015

0.2100 USD

Put Option / (1.00 : 100.00)

Selling

9 (900)

33.0000 USD

AMERICAN

20/11/2015

0.2500 USD

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

Call Warrant

Selling

20,000

36.0000 USD

AMERICAN

18/12/2015

0.0280 EUR

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

Call Warrant

Selling

3,000

32.0000 USD

AMERICAN

18/03/2016

0.2800 EUR

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 3)

 

3.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities 

under any option referred to on this form or relating to the voting rights or future

 acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

Date of disclosure

09 November 2015

Contact name

Aadithya Rao and Yiannis Bardis

Telephone number

+44(20) 7051 9046 / +44(20) 7774 7107

Name of offeree/offeror with which connected

Pfizer Inc

Nature of connection (Note 6)

Advisor to Offeror

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEEAFFNESDSFFF
Date   Source Headline
4th Nov 20155:37 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:37 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:35 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:34 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20153:33 pmRNSForm 8.3 - Allergan plc
4th Nov 20153:30 pmRNSForm 8.3 - Pfizer Inc. - Amendment
4th Nov 20153:29 pmRNSForm 8.3 - Pfizer Inc.
4th Nov 20153:26 pmRNSForm 8.3 - Pfizer Inc.
4th Nov 20153:20 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20153:20 pmRNSForm 8.3 - PFIZER INC
4th Nov 20153:18 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20153:17 pmRNSForm 8.3 - ALLERGAN PLC
4th Nov 20153:07 pmBUSForm 8.3 - Pfizer Inc.
4th Nov 20153:06 pmRNSForm 8.3 - Pfizer Inc
4th Nov 20152:54 pmRNSForm 8.3 - Pfizer, Inc.
4th Nov 20152:27 pmRNSForm 8.3 - Pfizer Inc
4th Nov 20151:20 pmRNSForm 8.1 - [Pfizer Inc]
4th Nov 20151:16 pmRNSForm 38.5a
4th Nov 20151:13 pmRNSForm 38.5b
4th Nov 20151:12 pmRNSForm 38.5b
4th Nov 201512:03 pmRNSForm 38.5(b) - Pfizer Inc.
4th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
4th Nov 201511:42 amRNSForm 38.5(a) - Pfizer Inc.
4th Nov 201511:33 amRNSRule 8.1 - Pfizer INC
4th Nov 201511:32 amRNSRule 38.5 - Pfizer INC
4th Nov 201511:32 amRNSRule 38.5 - Pfizer INC
4th Nov 201511:31 amRNSRule 38.5 - Pfizer INC
3rd Nov 20156:04 pmRNSForm 38.5a
3rd Nov 20156:02 pmRNSForm 38.5b
3rd Nov 20156:01 pmRNSForm 8.1 - [Pfizer]
3rd Nov 20155:57 pmRNSForm 8.1 - [Pfizer]
3rd Nov 20155:55 pmRNSForm 38.5b
3rd Nov 20153:49 pmRNSForm 8.3 - Allergan plc
3rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
3rd Nov 20153:20 pmRNSForm 8.3 - [PFIZER INC]
3rd Nov 20153:15 pmRNSForm 8.3 - Pfizer, Inc.
3rd Nov 20153:00 pmRNSForm 8.3 - PFIZER INC
3rd Nov 20152:59 pmRNSForm 8.3 - ALLERGAN PLC
3rd Nov 20152:57 pmRNSForm 8.3 - Pfizer Inc. - Amendment
3rd Nov 20152:55 pmRNSForm 8.3 - Pfizer Inc.
3rd Nov 20152:35 pmRNSForm 8.3 - Pfizer Inc
3rd Nov 20152:32 pmBUSForm 8.3 - Pfizer Inc.
3rd Nov 20152:15 pmRNSForm 8.3 - Allergan Plc
3rd Nov 201512:01 pmRNSForm 38.5(b) - Pfizer Inc.
3rd Nov 201511:56 amRNSRule 38.5 - Pfizer INC
3rd Nov 201511:54 amRNSRule 38.5 - Pfizer INC
3rd Nov 201511:54 amRNSRule 38.5 - Pfizer INC
3rd Nov 201511:09 amRNSForm 38.5(b) - Pfizer Inc.
3rd Nov 201511:08 amRNSForm 38.5(b) - Pfizer Inc.- Amendment
3rd Nov 20157:00 amRNSForm 8.3 - Pfizer, Inc.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.